CN Patent

CN115515687A — 2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁烷-3-基)哌嗪-1-基]戊-2-烯腈的固体形式

Assigned to Principia Biopharma Inc · Expires 2022-12-23 · 3y expired

What this patent protects

公开了化合物(I)的固体形式。还公开了包含化合物(I)的固体形式的药物组合物、使用其治疗由BTK活性介导的障碍和病症的方法、以及用于制造化合物(I)及其固体形式的方法。

USPTO Abstract

公开了化合物(I)的固体形式。还公开了包含化合物(I)的固体形式的药物组合物、使用其治疗由BTK活性介导的障碍和病症的方法、以及用于制造化合物(I)及其固体形式的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN115515687A
Jurisdiction
CN
Classification
—
Expires
2022-12-23
Drug substance claim
No
Drug product claim
No
Assignee
Principia Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.